Related Experiment Videos
Fatal liver failure in 16 children with valproate therapy.
D Scheffner1, S König, I Rauterberg-Ruland
1University Children's Hospital, Berlin, F.R.G.
Epilepsia
|September 1, 1988
Summary
Valproate (VPA) treatment in children has been linked to fatal liver failure, particularly within the first six months. Close monitoring for symptoms like vomiting and apathy is crucial for patient safety.
Area of Science:
- Pediatric Pharmacology
- Hepatology
- Toxicology
Background:
- Valproate (VPA) is an anticonvulsant medication with known risks.
- Fatal hepatotoxicity has been reported in children receiving VPA therapy.
Purpose of the Study:
- To analyze the clinical and pathological data of children who died during VPA therapy.
- To identify risk factors and clinical indicators of VPA-induced fatal liver failure.
Main Methods:
- Retrospective analysis of 16 pediatric cases of VPA-associated fatalities in West Germany.
- Review of clinical symptoms, laboratory tests, and liver histology.
- Detection of VPA metabolites in patient samples.
Main Results:
- Hepatotoxicity symptoms included nausea, vomiting, and apathy, progressing to liver failure.
- Liver histology showed microvesicular steatosis, necrosis, and bile duct proliferation.
- An abnormal metabolite, 4-ene-VPA, was detected in all tested patients and persisted post-withdrawal.
Conclusions:
- Fatal liver failure during VPA treatment is a serious concern, especially in children.
- Early detection through monitoring of clinical signs (vomiting, apathy) and lab tests is vital.
- Careful reevaluation of VPA indication and rigorous monitoring are necessary due to the significant risk of fatalities.